These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 24929039)

  • 21. Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system.
    Jain RA; Rhodes CT; Railkar AM; Malick AW; Shah NH
    J Microencapsul; 2000; 17(3):343-62. PubMed ID: 10819422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of PLGA-based injectable delivery systems for hydrophobic fenretinide.
    Wischke C; Zhang Y; Mittal S; Schwendeman SP
    Pharm Res; 2010 Oct; 27(10):2063-74. PubMed ID: 20668921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poly (lactic-co-glycolic acid) as a controlled release delivery device.
    Lim TY; Poh CK; Wang W
    J Mater Sci Mater Med; 2009 Aug; 20(8):1669-75. PubMed ID: 19283453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein instability in poly(lactic-co-glycolic acid) microparticles.
    van de Weert M; Hennink WE; Jiskoot W
    Pharm Res; 2000 Oct; 17(10):1159-67. PubMed ID: 11145219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality by design thinking in the development of long-acting injectable PLGA/PLA-based microspheres for peptide and protein drug delivery.
    Zhang C; Yang L; Wan F; Bera H; Cun D; Rantanen J; Yang M
    Int J Pharm; 2020 Jul; 585():119441. PubMed ID: 32442645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of PLGA-based itraconazole injectable nanospheres for sustained release.
    Bian X; Liang S; John J; Hsiao CH; Wei X; Liang D; Xie H
    Int J Nanomedicine; 2013; 8():4521-31. PubMed ID: 24311942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of the microencapsulation method and peptide loading on poly(lactic acid) and poly(lactic-co-glycolic acid) degradation during in vitro testing.
    Witschi C; Doelker E
    J Control Release; 1998 Feb; 51(2-3):327-41. PubMed ID: 9685930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3.
    Bol GM; Khan R; Heerma van Voss MR; Tantravedi S; Korz D; Kato Y; Raman V
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):821-7. PubMed ID: 26330329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers.
    Okada H; Doken Y; Ogawa Y; Toguchi H
    Pharm Res; 1994 Aug; 11(8):1143-7. PubMed ID: 7971715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a cell transducible RhoA inhibitor TAT-C3 transferase and its encapsulation in biocompatible microspheres to promote survival and enhance regeneration of severed neurons.
    Tan EY; Law JW; Wang CH; Lee AY
    Pharm Res; 2007 Dec; 24(12):2297-308. PubMed ID: 17899323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a sustained-release system for perivascular delivery of dipyridamole.
    Zhu W; Masaki T; Bae YH; Rathi R; Cheung AK; Kern SE
    J Biomed Mater Res B Appl Biomater; 2006 Apr; 77(1):135-43. PubMed ID: 16206204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid oligomers: Part II. Biodegradation and drug delivery application.
    Wang N; Wu XS
    J Biomater Sci Polym Ed; 1997; 9(1):75-87. PubMed ID: 9505204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carboplatin-loaded PLGA microspheres for intracerebral injection: formulation and characterization.
    Chen W; Lu DR
    J Microencapsul; 1999; 16(5):551-63. PubMed ID: 10499836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poly(lactic-co-glycolic) acid-controlled-release systems: experimental and modeling insights.
    Hines DJ; Kaplan DL
    Crit Rev Ther Drug Carrier Syst; 2013; 30(3):257-76. PubMed ID: 23614648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of various injectable protein-loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices: in-situ-formed implant versus in-situ-formed microspheres versus isolated microspheres.
    Jain RA; Rhodes CT; Railkar AM; Malick AW; Shah NH
    Pharm Dev Technol; 2000; 5(2):201-7. PubMed ID: 10810750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of attributes and in vitro performance of exenatide-loaded PLGA long-acting release microspheres.
    Li T; Chandrashekar A; Beig A; Walker J; Hong JKY; Benet A; Kang J; Ackermann R; Wang Y; Qin B; Schwendeman AS; Schwendeman SP
    Eur J Pharm Biopharm; 2021 Jan; 158():401-409. PubMed ID: 33122118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles, and sterilization process.
    Herrero-Vanrell R; Ramirez L; Fernandez-Carballido A; Refojo MF
    Pharm Res; 2000 Oct; 17(10):1323-8. PubMed ID: 11145241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of PLGA raw materials on in vitro and in vivo performance of drug-loaded microspheres.
    Liang D; Walker J; Schwendeman PS; Chandrashekar A; Ackermann R; Olsen KF; Beck-Broichsitter M; Schwendeman SP
    Drug Deliv Transl Res; 2024 Apr; ():. PubMed ID: 38643259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Controlled release from coated polymer microparticles embedded in tissue-engineered scaffolds.
    Hu Y; Hollinger JO; Marra KG
    J Drug Target; 2001; 9(6):431-8. PubMed ID: 11822815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lysozyme release and polymer erosion behavior of injectable implants prepared from PLGA-PEG block copolymers and PLGA/PLGA-PEG blends.
    Vesna Milacic VM; Schwendeman SP
    Pharm Res; 2014 Feb; 31(2):436-48. PubMed ID: 23959854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.